Recognition Versus Adaptive Up-regulation and Degradation of CC Chemokines by the Chemokine Decoy Receptor D6 Are Determined by Their N-terminal Sequence*
暂无分享,去创建一个
A. Mantovani | P. Proost | E. Borroni | R. Bonecchi | M. Locati | S. Struyf | A. Mortier | B. Savino | N. Torres
[1] G. Opdenakker,et al. Synergistic up‐regulation of MCP‐2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti‐tumoral effects , 2009, European journal of immunology.
[2] P. Proost,et al. Regulation of chemokine activity by posttranslational modification. , 2008, Pharmacology & therapeutics.
[3] A. Mantovani,et al. Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection , 2008, The Journal of experimental medicine.
[4] G. Opdenakker,et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation , 2008, The Journal of experimental medicine.
[5] T. Schwartz,et al. Positive Versus Negative Modulation of Different Endogenous Chemokines for CC-chemokine Receptor 1 by Small Molecule Agonists through Allosteric Versus Orthosteric Binding* , 2008, Journal of Biological Chemistry.
[6] A. Mantovani,et al. Regulation of D6 chemokine scavenging activity by ligand- and Rab11-dependent surface up-regulation. , 2008, Blood.
[7] T. Chun,et al. Structural and functional characterization of CC chemokine CCL14. , 2007, Biochemistry.
[8] R. Nibbs,et al. The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. , 2007, The Journal of clinical investigation.
[9] A. Mantovani,et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6 , 2007, Proceedings of the National Academy of Sciences.
[10] P. Proost,et al. Natural post-translational modifications of chemokines. , 2006, Biochemical Society transactions.
[11] Alberto Mantovani,et al. Tuning inflammation and immunity by chemokine sequestration: decoys and more , 2006, Nature Reviews Immunology.
[12] R. Ransohoff,et al. The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.
[13] A. Mantovani,et al. Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines. , 2005, Cytokine & growth factor reviews.
[14] T. Handel,et al. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. , 2005, Cytokine & growth factor reviews.
[15] B. Premack,et al. Proteolytic Activation of Alternative CCR1 Ligands in Inflammation1 , 2005, The Journal of Immunology.
[16] Alberto Mantovani,et al. Increased inflammation in mice deficient for the chemokine decoy receptor D6 , 2005, European journal of immunology.
[17] Antonio Alcami,et al. The chemokine receptor D6 limits the inflammatory response in vivo , 2005, Nature Immunology.
[18] M. Walden,et al. n-Nonanoyl-CC Chemokine Ligand 14, a Potent CC Chemokine Ligand 14 Analogue That Prevents the Recruitment of Eosinophils in Allergic Airway Inflammation1 , 2004, The Journal of Immunology.
[19] M. Gobbi,et al. Differential Recognition and Scavenging of Native and Truncated Macrophage-Derived Chemokine (Macrophage-Derived Chemokine/CC Chemokine Ligand 22) by the D6 Decoy Receptor1 , 2004, The Journal of Immunology.
[20] Marc Parmentier,et al. The Core Domain of Chemokines Binds CCR5 Extracellular Domains while Their Amino Terminus Interacts with the Transmembrane Helix Bundle* , 2003, The Journal of Biological Chemistry.
[21] M. Parmentier,et al. Urokinase Plasminogen Activator and Plasmin Efficiently Convert Hemofiltrate CC Chemokine 1 into Its Active [9–74] Processed Variant1 , 2001, The Journal of Immunology.
[22] W. Forssmann,et al. Hemofiltrate CC chemokines with unique biochemical properties: HCC‐1/CCL14a and HCC‐2/CCL15 , 2001, Journal of leukocyte biology.
[23] D. Kerjaschki,et al. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. , 2001, The American journal of pathology.
[24] F. Kirchhoff,et al. Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properties , 2000, The Journal of experimental medicine.
[25] P. Proost,et al. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. , 2000, Blood.
[26] K. Matsushima,et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.
[27] T. Schwartz,et al. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. , 2000, Molecular pharmacology.
[28] J. Mao,et al. LD78β, A Non-allelic Variant of Human MIP-1α (LD78α), Has Enhanced Receptor Interactions and Potent HIV Suppressive Activity* , 1999, The Journal of Biological Chemistry.
[29] A. Mantovani,et al. The chemokine system: redundancy for robust outputs. , 1999, Immunology today.
[30] P. Murphy,et al. The CXC Chemokines Growth-regulated Oncogene (GRO) α, GROβ, GROγ, Neutrophil-activating Peptide-2, and Epithelial Cell-derived Neutrophil-activating Peptide-78 Are Potent Agonists for the Type B, but Not the Type A, Human Interleukin-8 Receptor* , 1996, The Journal of Biological Chemistry.
[31] M. Raida,et al. HCC-1, a novel chemokine from human plasma , 1996, The Journal of experimental medicine.
[32] A. Mantovani,et al. Chemokines and chemokine receptors: an overview. , 2009, Frontiers in bioscience.
[33] P. Proost,et al. Regulation of the immune response by the interaction of chemokines and proteases. , 2003, Advances in immunology.